The human metabolome reflects a complex interplay of genetic and environmental factors. A large-scale analysis integrating blood metabolomic, genomic, and lifestyle data from ten prospective cohorts has identified a comprehensive profile of circulating metabolites that are associated with the future risk of developing type 2 diabetes (T2D).¹
Methodology
Researchers conducted a pooled analysis of 23,634 participants who were initially free from T2D, from ten prospective cohorts including the Nurses’ Health Study (NHS) and the Atherosclerosis Risk in Communities (ARIC) study. Over a follow-up period of up to 26 years, 4,000 incident T2D cases were identified. The study examined 469 harmonised circulating metabolites to identify associations with incident T2D.
Results
The meta-analysis identified 235 metabolites significantly associated with incident T2D, even after adjusting for factors such as body mass index (BMI). Of these, 67 were novel associations not previously reported, implicating pathways in bile acid, lipid, carnitine, urea cycle, and amino acid metabolism. Genetic analyses linked these T2D-associated metabolites to key pathophysiological mechanisms, including insulin resistance, ectopic fat deposition, and liver function. Lifestyle factors, particularly physical activity, obesity, and diet, were found to explain a greater variation in T2D-associated metabolites compared to non-associated ones. Furthermore, a 44-metabolite signature was developed that improved T2D risk prediction beyond conventional risk factors.
In Practice
The study authors suggest, "These findings provide a foundation for understanding T2D mechanisms and may inform precision prevention targeting specific metabolic pathways." The identification of these metabolites and their links to both genetic and modifiable risk factors offers new insights into T2D aetiology. The 44-metabolite signature could serve as a valuable tool for risk stratification, helping to identify high-risk individuals for early and targeted preventive interventions.
Next Steps
Further research is needed to validate the metabolomic signature in diverse populations and clinical settings. The specific metabolic pathways highlighted in this study may also represent promising targets for future therapeutic strategies aimed at preventing T2D.
This study was funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), and the National Human Genome Research Institute (NHGRI).
References
1. Li J, Hu J, Yun H, et al. Circulating metabolites, genetics and lifestyle factors in relation to future risk of type 2 diabetes. Nat Med (2026). https://doi.org/10.1038/s41591-025-04105-8
Disclaimer
The information presented in this article is for educational purposes only. Any quotes included reflect the opinions of the individual quoted, and do not necessarily reflect the views of the publisher. The publisher does not guarantee the accuracy or completeness of the content and accepts no responsibility for any errors, or any consequences arising from its use.